Edwards Lifesciences Corporation logo
EWEdwards Lifesciences Corporation

Quick Ratio (Acid-Test): 3.63

popular:market cap|pe ratio|revenue|price history|total return

Is the quick ratio (acid-test) high or low?

The quick ratio (acid-test) of 3.63 is 26% above its 5-year average of 2.88, near the high end of its 5-year range (2.17–3.87).

As of Sunday, June 28, 2026. 3.42% above its 12-month average of 3.51.

Current Ratio|Debt to Equity|P/FCF Ratio|All Metrics
Quick Ratio

EW Quick Ratio

3.63

Reported quarterly quick ratio; no daily interpolation.

+25.37% 5Y
EW Quick Ratio (Acid-Test)

EW Average Quick Ratio (Acid-Test) Chart

EW Quick Ratio (Acid-Test)

EW Current vs Average Quick Ratio (Acid-Test) Chart

EW Quick Ratio (Acid-Test) Metrics

QUICK RATIO (ACID-TEST)

3.63

QUICK RATIO (ACID-TEST) AVG TTM

3.51

QUICK RATIO (ACID-TEST) AVG 3Y

3.00

QUICK RATIO (ACID-TEST) AVG 5Y

2.83

QUICK RATIO (ACID-TEST) AVG 10Y

2.75

QUICK RATIO (ACID-TEST) AVG 15Y

2.98

QUICK RATIO (ACID-TEST) AVG 20Y

2.78

CURRENT VS TTM AVG

+3.42%

CURRENT VS 3Y AVG

+21.02%

CURRENT VS 5Y AVG

+28.30%

CURRENT VS 10Y AVG

+31.88%

CURRENT VS 15Y AVG

+21.57%

CURRENT VS 20Y AVG

+30.32%

EW Competitors' Quick Ratio (Acid-Test)

NAMEMARKET CAPQUICK RATIO (ACID-TEST)TTM3Y5Y
Edwards Lifesciences Corporation (EW)$52.27B3.633.513.002.83
Cencora, Inc. (COR)vs ›$55.67B0.550.540.530.55
Cardinal Health, Inc. (CAH)vs ›$55.72B0.500.530.540.55
Becton, Dickinson and Company (BDX)vs ›$56.49B0.640.690.700.80
Humana Inc. (HUM)vs ›$46.08B0.720.580.570.58
IDEXX Laboratories, Inc. (IDXX)vs ›$43.50B0.840.900.890.98
Regeneron Pharmaceuticals, Inc. (REGN)vs ›$65.20B3.393.674.143.76
Boston Scientific Corporation (BSX)vs ›$65.74B1.080.860.891.02
Agilent Technologies, Inc. (A)vs ›$38.41B1.521.541.631.68
Medline Inc. (MDLN)vs ›$32.87B2.371.972.092.09

Liquidity Comparison

Quick Ratio

3.63

Excludes inventory

Current Ratio

3.72

Includes inventory

Quick Ratio (Acid-Test) Formula & Definition

Quick Ratio = (Current Assets − Inventory) / Current Liabilities

The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Quick Ratio (Acid-Test) FAQ

What is the quick ratio (acid-test) for Edwards Lifesciences Corporation (EW)?
The quick ratio (acid-test) for EW stock is 3.63.
Is Edwards Lifesciences Corporation's quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 3.63 is 26% above its 5-year average of 2.88, near the high end of its 5-year range (2.17–3.87).
What is the TTM average quick ratio (acid-test) for Edwards Lifesciences Corporation (EW)?
The TTM average quick ratio (acid-test) for EW stock is 3.51.
What is the 3Y average quick ratio (acid-test) for Edwards Lifesciences Corporation (EW)?
The 3Y average quick ratio (acid-test) for EW stock is 3.00.
What is the 5Y average quick ratio (acid-test) for Edwards Lifesciences Corporation (EW)?
The 5Y average quick ratio (acid-test) for EW stock is 2.83.
What is the 10Y average quick ratio (acid-test) for Edwards Lifesciences Corporation (EW)?
The 10Y average quick ratio (acid-test) for EW stock is 2.75.
What is the 15Y average quick ratio (acid-test) for Edwards Lifesciences Corporation (EW)?
The 15Y average quick ratio (acid-test) for EW stock is 2.98.
What is the 20Y average quick ratio (acid-test) for Edwards Lifesciences Corporation (EW)?
The 20Y average quick ratio (acid-test) for EW stock is 2.78.

EW Quick Ratio (Acid-Test) History

DATEQUICK RATIO (ACID-TEST)
2026-03-313.63
2025-12-313.09
2025-09-303.29
2025-06-303.87
2025-03-313.66
2024-12-313.45
2024-09-302.89
2024-06-302.87
2024-03-312.67
2023-12-312.62
2023-09-302.45
2023-06-302.30
2023-03-312.17
2022-12-312.17
2022-09-303.00
2022-06-302.60
2022-03-312.64
2021-12-312.38
2021-09-302.87
2021-06-302.89
2021-03-312.88
2020-12-312.56
2020-09-302.61
2020-06-302.24
2020-03-312.47
2019-12-312.60
2019-09-302.74
2019-06-302.48
2019-03-312.69
2018-12-311.92
2018-09-301.85
2018-06-301.80
2018-03-311.63
2017-12-311.41
2017-09-302.76
2017-06-303.19
2017-03-312.71
2016-12-313.46
2016-09-303.32
2016-06-303.38
2016-03-313.19
2015-12-313.59
2015-09-303.40
2015-06-304.46
2015-03-314.83
2014-12-314.60
2014-09-304.69
2014-06-303.63
2014-03-313.64
2013-12-314.10
2013-09-303.75
2013-06-303.47
2013-03-313.57
2012-12-312.91
2012-09-303.69
2012-06-303.56
2012-03-313.47
2011-12-312.71
2011-09-303.09
2011-06-303.15
2011-03-312.09
2010-12-312.45
2010-09-302.77
2010-06-302.97
2010-03-312.88
2009-12-312.49
2009-09-302.46
2009-06-302.39
2009-03-312.51
2008-12-312.09
2008-09-302.32
2008-06-302.20
2008-03-311.15
2007-12-311.14
2007-09-301.17
2007-06-301.23
2007-03-312.23
2006-12-311.72
2006-09-301.65
2006-06-301.78
2006-03-311.98
2005-12-311.97
2005-09-301.44
2005-06-301.61
2005-03-311.56
2004-12-311.23
2004-09-301.21
2004-06-301.37
2004-03-311.36
2003-12-311.43
2003-09-301.41
2003-06-301.41
2003-03-311.24
2002-12-311.08
2002-09-301.22
2002-06-301.19

Related Metrics

Current RatioDebt to EquityP/FCF RatioAll Metrics

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

Irvine, CA
15,800 employees
www.edwards.com
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Bernard J. Zovighian
View full financials